Oxervate (cenegermin) is a protein pharmaceutical. Cenegermin was first approved as Oxervate on 2017-07-06. It is used to treat keratitis in the USA. It has been approved in Europe to treat keratitis. The pharmaceutical is active against beta-nerve growth factor. In addition, it is known to target tumor necrosis factor receptor superfamily member 16.
|Drug Class||Growth factors|